However, while tumor AUC0–24 and Cmax also showed a dose-proportional increase for regorafenib, addition of anti-PD1 therapy to regorafenib 10 mg/kg further increased tumor exposure of the drug (online supplemental table S1 and online supplemental figure S1F, G). Here, PDCD1 is linked to neoplasm.